Introduction/Background A recent molecular cancer study suggested that inflammatory parameters such as neutrophils and platelet can facilitate tumor initiation, tumor progression, induction of angiogenesis and promote metastatic spreading by inhibiting the natural killer function. Therefore, the elevated absolute neutrophil count (ANC), platelet, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in many solid tumors are associated with a worse prognosis. However, only a few studies were conducted to further investigate this association in epithelial ovarian cancer (EOC), fallopian tube cancer (FT) and primary peritoneal cancer (PPA).

Objective To investigate the association of hematologic parameter and survival outcome in patients with EOC, FT and PPA who treated with platinum-based chemotherapy.

Methodology 306 medical records of patients with EOC, FT and PPA treated with platinum-based chemotherapy between 2007 and 2017 were reviewed. The association between pretreatment ANC, platelet, NLR and PLR with survival outcome were investigated by using receiver operating characteristic (ROC) curves analysis to determine the optimal cutoff values.

Results Nearly 80% were diagnosed as EOC. About one-fifth of the patients were received neoadjuvant chemotherapy followed by debulking surgery. Patients with high level of ANC (>5341 cell/cumm³), Platelet >325,000 cell/cumm³ NLR >3.3 and PLR >200.3 were significant more common in advanced stage (III&IV) and associated to poor survival outcome with hazard ratio at 1.632,2.072,2.113 and 2.113, respectively.

Conclusion Pretreatment hematologic parameters were associated to poor survival outcome.

Disclosure Nothing to disclose.